aziridine has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Romanchikova, N; Strazdina, J; Strods, A; Strumfs, B; Trapencieris, P | 1 |
1 other study(ies) available for aziridine and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Aziridines; Cell Line, Tumor; Down-Regulation; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serine; Transcription Factor RelA | 2016 |